Chapter
CROWN: 7-Year Update for Lorlatinib
From ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor by Bryant Furlow
Concepts
- Trial Efficacy
"After 7 years of follow-up, lorlatinib monotherapy’s median PFS still had not been met, and the 7-year PFS was 55%, reported study coauthor Tony S.K. Mok, MD, of the Chinese University of Hong Kong.2
- Brain Control
"Dr Mok emphasized the durability of that protection, pointing to a plateau in brain tumor progression and the development of new brain metastases after 36 months. Ninety-six percent of patients in th
- Safety Profile
"Lorlatinib’s safety was consistent with earlier analyses, with no new signals during follow-up. Most grade 3 or 4 adverse events since the prior 5-year analysis were increased lipid values, Dr Mok re
- Chronic Disease
"With this evidence of durable control of intracranial and extracranial disease, Dr Mok said lorlatinib has the potential to transform advanced ALK-positive NSCLC into a chronic disease for some patie